TW202311248A - 經取代之雜環化合物 - Google Patents

經取代之雜環化合物 Download PDF

Info

Publication number
TW202311248A
TW202311248A TW111118147A TW111118147A TW202311248A TW 202311248 A TW202311248 A TW 202311248A TW 111118147 A TW111118147 A TW 111118147A TW 111118147 A TW111118147 A TW 111118147A TW 202311248 A TW202311248 A TW 202311248A
Authority
TW
Taiwan
Prior art keywords
compound
compounds
disease
mmol
pharmaceutically acceptable
Prior art date
Application number
TW111118147A
Other languages
English (en)
Chinese (zh)
Inventor
史帝芬 H 史伯傑爾
雷恩 M 莫斯林
麥可 艾德華 馬提斯曼
Original Assignee
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW202311248A publication Critical patent/TW202311248A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111118147A 2021-05-14 2022-05-13 經取代之雜環化合物 TW202311248A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US63/188,498 2021-05-14
US202263318508P 2022-03-10 2022-03-10
US63/318,508 2022-03-10

Publications (1)

Publication Number Publication Date
TW202311248A true TW202311248A (zh) 2023-03-16

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118147A TW202311248A (zh) 2021-05-14 2022-05-13 經取代之雜環化合物

Country Status (12)

Country Link
US (2) US11884650B2 (https=)
EP (1) EP4337648B1 (https=)
JP (1) JP7818623B2 (https=)
KR (1) KR20240008338A (https=)
AU (1) AU2022272725A1 (https=)
BR (1) BR112023023726A2 (https=)
CA (1) CA3218579A1 (https=)
ES (1) ES3059456T3 (https=)
IL (1) IL308422A (https=)
MX (1) MX2023013351A (https=)
TW (1) TW202311248A (https=)
WO (1) WO2022241174A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI893772B (zh) * 2023-04-21 2025-08-11 大陸商浙江文達醫藥科技有限公司 作為tyk2抑制劑的雜環化合物及合成與應用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492184B2 (en) 2020-12-22 2025-12-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
JP2024518791A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 IL-12, IL-23 및/또는 IFNα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
AU2019373203B2 (en) * 2018-10-30 2024-10-24 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
AU2021254764A1 (en) * 2020-04-14 2022-11-03 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
PE20250262A1 (es) * 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
JP2024518791A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI893772B (zh) * 2023-04-21 2025-08-11 大陸商浙江文達醫藥科技有限公司 作為tyk2抑制劑的雜環化合物及合成與應用

Also Published As

Publication number Publication date
EP4337648B1 (en) 2025-12-24
AU2022272725A1 (en) 2024-01-04
IL308422A (en) 2024-01-01
MX2023013351A (es) 2023-11-27
EP4337648A1 (en) 2024-03-20
KR20240008338A (ko) 2024-01-18
JP2024518555A (ja) 2024-05-01
US11884650B2 (en) 2024-01-30
WO2022241174A1 (en) 2022-11-17
US20240124421A1 (en) 2024-04-18
US20220388987A1 (en) 2022-12-08
BR112023023726A2 (pt) 2024-01-30
ES3059456T3 (en) 2026-03-20
JP7818623B2 (ja) 2026-02-20
CA3218579A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
JP7490107B2 (ja) スルホンピリジンアルキルアミド置換ヘテロアリール化合物
US11884650B2 (en) Substituted heterocyclic compounds
JP6458038B2 (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
KR102602558B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물
JP7637626B2 (ja) アミド二置換のピリジンまたはピリダジン化合物
JP2019501125A (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
US20240270723A1 (en) Substituted heterocyclic compounds
US20250066322A1 (en) Substituted heterocyclic compounds
KR20240008339A (ko) 치환된 헤테로시클릭 화합물
JP2019532092A (ja) Il−12、il−23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物
CN117321045A (zh) 经取代的杂环化合物
CN117355514A (zh) 经取代的杂环化合物
EA047032B1 (ru) Замещенные гетероциклические соединения
KR20250099236A (ko) 치환된 헤테로시클릭 화합물